1
|
Olšovská E, Mikušová ML, Tulinská J, Rollerová E, Vilamová Z, Líšková A, Horváthová M, Szabová M, Svoboda L, Gabor R, Hajnyš J, Dvorský R, Kukutschová J, Lukán N. Immunotoxicity of stainless-steel nanoparticles obtained after 3D printing. ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY 2024; 272:116088. [PMID: 38350218 DOI: 10.1016/j.ecoenv.2024.116088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Revised: 01/30/2024] [Accepted: 02/06/2024] [Indexed: 02/15/2024]
Abstract
This study aims to investigate the in vitro effects of nanoparticles (NPs) produced during the selective laser melting (SLM) of 316 L stainless steel metal powder on the immune response in a human blood model. Experimental data did not reveal effect on viability of 316 L NPs for the tested doses. Functional immune assays showed a significant immunosuppressive effect of NPs. There was moderate stimulation (117%) of monocyte phagocytic activity without significant changes in phagocytic activity and respiratory burst of granulocytes. A significant dose-dependent increase in the levels of the pro-inflammatory cytokine TNF-a was found in blood cultures treated with NPs. On the contrary, IL-8 chemokine levels were significantly suppressed. The levels of the pro-inflammatory cytokine IL-6 were reduced by only a single concentration of NPs. These new findings can minimise potential health risks and indicate the need for more research in this area.
Collapse
Affiliation(s)
- Eva Olšovská
- Nanotechnology Centre, CEET, VSB-Technical University of Ostrava, 17. listopadu 2172/15, Ostrava-Poruba 708 00, Czech Republic; Faculty of Material Science and Technology, Centre for Advanced Innovation Technologies, VSB-Technical University of Ostrava, 17. listopadu 2172/15, Ostrava-Poruba 708 00, Czech Republic.
| | - Miroslava Lehotská Mikušová
- Institute of Immunology and Allergology, Faculty of Medicine, Slovak Medical University, Limbová 12, 833 03, Slovakia
| | - Jana Tulinská
- Institute of Immunology and Allergology, Faculty of Medicine, Slovak Medical University, Limbová 12, 833 03, Slovakia
| | - Eva Rollerová
- Institute of Immunology and Allergology, Faculty of Medicine, Slovak Medical University, Limbová 12, 833 03, Slovakia
| | - Zuzana Vilamová
- Nanotechnology Centre, CEET, VSB-Technical University of Ostrava, 17. listopadu 2172/15, Ostrava-Poruba 708 00, Czech Republic; Faculty of Materials and Technology, VSB-Technical University of Ostrava, 17. listopadu 2172/15, Ostrava-Poruba 708 00, Czech Republic
| | - Aurélia Líšková
- Institute of Immunology and Allergology, Faculty of Medicine, Slovak Medical University, Limbová 12, 833 03, Slovakia
| | - Mira Horváthová
- Institute of Immunology and Allergology, Faculty of Medicine, Slovak Medical University, Limbová 12, 833 03, Slovakia
| | - Michaela Szabová
- Institute of Immunology and Allergology, Faculty of Medicine, Slovak Medical University, Limbová 12, 833 03, Slovakia
| | - Ladislav Svoboda
- Nanotechnology Centre, CEET, VSB-Technical University of Ostrava, 17. listopadu 2172/15, Ostrava-Poruba 708 00, Czech Republic
| | - Roman Gabor
- Nanotechnology Centre, CEET, VSB-Technical University of Ostrava, 17. listopadu 2172/15, Ostrava-Poruba 708 00, Czech Republic
| | - Jiří Hajnyš
- Department of Machining, Assembly and Engineering Metrology, Faculty of Mechanical Engineering, VSB-Technical University of Ostrava, 17. listopadu 2172/15, Ostrava-Poruba 708 00, Czech Republic
| | - Richard Dvorský
- Nanotechnology Centre, CEET, VSB-Technical University of Ostrava, 17. listopadu 2172/15, Ostrava-Poruba 708 00, Czech Republic
| | - Jana Kukutschová
- Faculty of Material Science and Technology, Centre for Advanced Innovation Technologies, VSB-Technical University of Ostrava, 17. listopadu 2172/15, Ostrava-Poruba 708 00, Czech Republic
| | - Norbert Lukán
- Institute of Immunology and Allergology, Faculty of Medicine, Slovak Medical University, Limbová 12, 833 03, Slovakia
| |
Collapse
|
2
|
de Macêdo LS, de Pinho SS, Silva AJD, de Moura IA, Espinoza BCF, da Conceição Viana Invenção M, Novis PVS, da Gama MATM, do Nascimento Carvalho M, Leal LRS, Cruz BIS, Bandeira BMA, Santos VEP, de Freitas AC. Understanding yeast shells: structure, properties and applications. ADMET AND DMPK 2024; 12:299-317. [PMID: 38720922 PMCID: PMC11075163 DOI: 10.5599/admet.2118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2023] [Revised: 02/13/2024] [Indexed: 05/12/2024] Open
Abstract
Background and purpose The employment of yeasts for biomedical purposes has become increasingly frequent for the delivery of prophylactic and therapeutic products. Its structural components, such as β-glucans, mannan, and chitin, can be explored as immunostimulators that show safety and low toxicity. Besides, this system minimizes antigen degradation after administration, facilitating the delivery to the target cells. Review approach This review sought to present molecules derived from yeast, called yeast shells (YS), and their applications as carrier vehicles for drugs, proteins, and nucleic acids for immunotherapy purposes. Furthermore, due to the diversity of information regarding the production and immunostimulation of these compounds, a survey of the protocols and immune response profiles generated was presented. Key results The use of YS has allowed the development of strategies that combine efficiency and effectiveness in antigen delivery. The capsular structure can be recognized and phagocytized by dendritic cells and macrophages. In addition, the combination with different molecules, such as nanoparticles or even additional adjuvants, improves the cargo loading, enhancing the system. Activation by specific immune pathways can also be achieved by different administration routes. Conclusion Yeast derivatives combined in different ways can increase immunostimulation, enhancing the delivery of medicines and vaccine antigens. These aspects, combined with the simplicity of the production steps, make these strategies more accessible to be applied in the prevention and treatment of various diseases.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | - Antonio Carlos de Freitas
- Laboratory of Molecular Studies and Experimental Therapy - LEMTE; Department of Genetics, Biosciences Center, Federal University of Pernambuco; Pernambuco - Recife 50670-901, Brazil
| |
Collapse
|
3
|
Wen H, Huo G, Qin C, Wu H, Wang D, Dan M, Geng X, Liu S. Safety evaluation of PEGylated MNPs and p-PEGylated MNPs in SD rats. Sci Rep 2023; 13:21501. [PMID: 38057444 PMCID: PMC10700491 DOI: 10.1038/s41598-023-48742-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2023] [Accepted: 11/29/2023] [Indexed: 12/08/2023] Open
Abstract
Polyethylene glycol-coated magnetic nanoparticles (PEGylated MNPs) have demonstrated prominent advantages in cancer diagnosis and hyperthermia therapy. However, there is currently lack of standard mode and sufficient toxicity data for determining the delayed risk of PEGylated MNPs. Nevertheless, the toxicity potentials, especially those associated with the oxidative stress, were ubiquitously reported. In this study, PEGylated MNPs and p-PEGylated MNPs were administrated to SD (Sprague Dawley) rats by single intravenously injection, and various toxicity indicators were monitored till 56 days post-administration for a comprehensive toxicity evaluation. We revealed that both nanoparticles could be rapidly cleared from plasma and enter tissues, such as, liver, kidneys and spleen, and p-PEGylated MNP is less prone to be accumulated in the tissues, indicating a lower toxicity risk. PEGylated MNPs were more likely to up-regulate the expression levels of Th2 type cytokines and trigger inflammatory pathways, but no related pathological change was found. Both MNPs are not mutagenic, while recoverable mild DNA damage associated with the presence of nanoparticles might also be observed. This study demonstrated a research approach for the non-clinical safety evaluation of nanoparticles. It also provided comprehensive valuable safety data for PEGylated and p-PEGylated MNPs, for promoting the clinical application and bio-medical translation of such MNPs with PEG modifications in the cancer diagnosis and therapy.
Collapse
Affiliation(s)
- Hairuo Wen
- National Center for Safety Evaluation of Drugs, Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, National Institutes for Food and Drug Control, Beijing, 100176, People's Republic of China
| | - Guitao Huo
- National Center for Safety Evaluation of Drugs, Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, National Institutes for Food and Drug Control, Beijing, 100176, People's Republic of China
| | - Chao Qin
- National Center for Safety Evaluation of Drugs, Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, National Institutes for Food and Drug Control, Beijing, 100176, People's Republic of China
| | - Hui Wu
- National Center for Safety Evaluation of Drugs, Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, National Institutes for Food and Drug Control, Beijing, 100176, People's Republic of China
- China Pharmaceutical University, Nanjing, 211198, Jiangsu Province, People's Republic of China
| | - Dan Wang
- National Center for Safety Evaluation of Drugs, Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, National Institutes for Food and Drug Control, Beijing, 100176, People's Republic of China
- China Pharmaceutical University, Nanjing, 211198, Jiangsu Province, People's Republic of China
| | - Mo Dan
- National Center for Safety Evaluation of Drugs, Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, National Institutes for Food and Drug Control, Beijing, 100176, People's Republic of China.
- State Key Laboratory of Novel Pharmaceutical Preparations and Excipients, CSPC Pharmaceutical Group Co., Ltd., Shijiazhuang, 050035, Hebei, People's Republic of China.
| | - Xingchao Geng
- National Center for Safety Evaluation of Drugs, Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, National Institutes for Food and Drug Control, Beijing, 100176, People's Republic of China.
| | - Shujie Liu
- National Center for Safety Evaluation of Drugs, Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, National Institutes for Food and Drug Control, Beijing, 100176, People's Republic of China.
- Center for Drug Evaluation, National Medical Products Administration, Beijing, 100022, People's Republic of China.
| |
Collapse
|